^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    fludarabine IV

    i
    Other names: NSC 312887, NSC-312887, NSC312887
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    21h
    SZ4601: CAR-T Cell Therapy Targeting to CD19 for R/R ALL (clinicaltrials.gov)
    P1/2, N=196, Recruiting, The First Affiliated Hospital of Soochow University | Active, not recruiting --> Recruiting | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Aug 2024 --> Aug 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    24h
    A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases (clinicaltrials.gov)
    P1, N=52, Recruiting, Kite, A Gilead Company | Not yet recruiting --> Recruiting
    Enrollment open • Pan tumor
    |
    LRP4 (LDL Receptor Related Protein 4)
    |
    cyclophosphamide • fludarabine IV • KITE-363
    1d
    A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, Genentech, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cyclophosphamide • fludarabine IV • RG6540
    1d
    Unrelated Umbilical Cord Blood Transplantation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov)
    P=N/A, N=8, Enrolling by invitation, Institute of Hematology & Blood Diseases Hospital, China
    New trial
    |
    CD34 (CD34 molecule)
    |
    fludarabine IV
    2d
    A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy (clinicaltrials.gov)
    P1, N=36, Recruiting, Children's Oncology Group | Trial completion date: Jun 2026 --> Mar 2028 | Trial primary completion date: Jun 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    NF1 (Neurofibromin 1) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11)
    |
    RAS mutation • CBL mutation
    |
    cytarabine • methotrexate • leucovorin calcium • fludarabine IV • Rytelo (imetelstat) • Starasid (cytarabine ocfosfate)
    2d
    Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1 trial
    |
    TP53 (Tumor protein P53) • CD22 (CD22 Molecule)
    |
    TP53 mutation
    |
    cyclophosphamide • fludarabine IV
    2d
    Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia (clinicaltrials.gov)
    P2, N=20, Recruiting, Northside Hospital, Inc. | Trial completion date: Aug 2027 --> Aug 2028 | Trial primary completion date: Aug 2026 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV
    3d
    MyeChild 01: International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (clinicaltrials.gov)
    P3, N=700, Active, not recruiting, University of Birmingham | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cytarabine • cyclophosphamide • Mylotarg (gemtuzumab ozogamicin) • mitoxantrone • fludarabine IV • busulfan
    3d
    The INFLUENCE Trial: Improve CAR T cell therapy by optimizing fludarabine exposure (2025-523096-34-00)
    P2/3, N=20, Not yet recruiting, Prinses Maxima Centrum voor Kinderoncologie B.V.
    New P2/3 trial
    |
    fludarabine IV
    6d
    UHKT-PTC-TMI-1: Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS (clinicaltrials.gov)
    P1/2, N=16, Recruiting, Institute of Hematology and Blood Transfusion, Czech Republic
    New P1/2 trial
    |
    cyclophosphamide • melphalan • fludarabine IV
    6d
    Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Air Force Military Medical University, China
    New P1 trial
    |
    cyclophosphamide • fludarabine IV
    6d
    MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases (clinicaltrials.gov)
    P2, N=132, Recruiting, Masonic Cancer Center, University of Minnesota | Not yet recruiting --> Recruiting | Initiation date: Aug 2026 --> Apr 2026
    Enrollment open • Trial initiation date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • fludarabine IV • Grafapex (treosulfan)